Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency

International Urology and Nephrology

Volumn 46, Issue 5, 2014, Pages 1005-1012

  Brătescu, Lavinia Oltiţa ^a   Bârsan, Liliana ^b   Gârneaţǎ, Liliana ^b   Stanciu, Ana ^b   Lipan, Mariana ^b   Stancu, Simona Hildegard ^b   Mircescu, Gabriel ^b  

^a Sf Pantelimon International Healthcare Systems Dialysis Unit   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Hemodialysis patients; Intravenous iron; Iron deficiency; Serum hepcidin

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; HEPCIDIN 25; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SERUM ALBUMIN; TRANSFERRIN; UNCLASSIFIED DRUG; ERYTHROPOIETIN; HEPCIDIN 25, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROPOIESIS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; IRON DEFICIENCY; IRON OVERLOAD; IRON THERAPY; MALE; PREDICTOR VARIABLE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DEFICIENCY; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

C-REACTIVE PROTEIN; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMOGLOBINS; HEPCIDINS; HUMANS; IRON; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TRANSFERRIN;

EID: 84903694873     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-014-0696-z     Document Type: Article

References (43)

1. Cui Y, Wu Q, Zhou Y (2009) Iron-refractory iron deficiency anemia: new molecular mechanisms. Kidney Int 76:1137-1141
2. Tessitore N, Girelli D, Campostrini N et al (2010) Hepcidin is not useful biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 25:3996-4002
3. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT investigators (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019-2032
4. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA, Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators (2010) Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363:1146-1155
5. (1999) European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 14(Suppl 5)
6. Mircescu G, Gherman Cǎprioarǎ M, Covic M et al (2005) Romanian Society of Nephrology Guidelines-anemia secondary to chronic kidney disease. Infomedica, Bucharest
7. Rambod M, Kovesdy CP, Kalantar-Zadeh K (2008) Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 3:1691-1701
8. Hörl WH (2007) Clinical aspects of iron use in anemia of kidney disease. J Am Soc Nephrol 18:382-393
9. Erwin KHJM, Tjalsma H, Willems HL, Swinkels DW (2008) Hepcidin: from discovery to differential diagnosis. Haematologica 93:90-97 (Pubitemid 351156156)
10. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T (2005) Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 106:2196-2199 (Pubitemid 41291740)
11. Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T (2006) The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 107:328-333 (Pubitemid 43053559)
12. Zaritsky J, Young B, Gales B et al (2010) Reduction of serum hepcidin by haemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol 5(6):1010-1014
13. Zaritsky J, Young B, Wang H et al (2009) Hepcidin - a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4:1051-1056
14. Weiss G, Theurl I, Eder S et al (2009) Serum hepcidin concentration in chronic haemodialysis patients: associations and effect on dialysis, iron and erythropoietin therapy. Eur J Clin Investig 39:883-890
15. Peters HPE, Laarakkers CMM, Swinkels DW et al (2010) Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant 25:848-853
16. Costa E, Swinkels DW, Laarakkers CM et al (2009) Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol 122:226-229
17. Eleftheriadis T, Kartsios C, Liakopoulos V et al (2006) Does hepcidin affect erythropoiesis in hemodialysis patients? Acta Haematol 116:238-244 (Pubitemid 44795902)
18. Dallalio G, Law E, Means RT Jr (2006) Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 107:2702-2704
19. Brǎtescu LO, Bârsan DL, Munteanu D, Stancu S, Mircescu G (2010) Is hepcidin-25 a clinically relevant parameter for the haemodialysis patients' iron status. J Ren Nutr 20(Suppl 5):S77- S83
20. Macdougall IC, Malyszko J, Hider RC, Bansal SS (2010) Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol 5(9):1681-1689
21. Theurl I, Aigner E, Nairz M et al (2009) Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 113:5277-5286
22. Besarab A, Frinak S, Yee E (1999) An indistinct balance: the safety and efficacy of parenteral iron. J Am Soc Nephrol 10:2029-2043 (Pubitemid 29402526)
23. Bishu K, Agarwal R (2006) Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 1:S19-S23
24. Wish JB (2006) Assessing iron status: beyond serum ferritin and transferring saturation. Clin J Am Soc Nephrol 1:S4-S8
25. Kalantar-Zadeh K, Rodrigues RA, Humphreys MH (2004) Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19:141-149 (Pubitemid 38072625)
26. Coyne DW, Kapoian T, Suki W et al (2007) Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18(3):975-984 (Pubitemid 46434515)
27. Stancu S, Bârsan L, Stanciu A, Mircescu G (2010) Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 5(3):409-416
28. Himmerfarb J (2007) Iron regulation. J Am Soc Nephrol 18:379-381
29. Van der Putten K, Jie KE, Van den Broek D et al (2010) Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure. Eur J Heart Fail 12:943-950
30. Swinkels DW, Wetzels JFM (2008) Hepcidin: a new tool in the management of anemia in patients with chronic kidney disease? Nephrol Dial Transplant 23:2450-2453
31. Hamada Y, Fukagawa M (2009) Is hepcidin the star player in iron metabolism in chronic kidney disease? Kidney Int 75:873-874
32. Ganz T (2007) Molecular control of iron transport. J Am Soc Nephrol 18:394-400
33. Young B, Zaritsky J (2009) Hepcidin for clinicians. Clin J Am Soc Nephrol 4:1384-1387
34. Malyszko J, Malyszko JK, Mysliwiec M (2009) Serum prohepcidin and hepcidin in haemodialysed patients undergoing iron therapy. Kidney Blood Press Res 32:235-238
35. Tessitore N, Solero GP, Lippi G et al (2001) The role of iron status markers in predicting response to intravenous iron in hemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16:1416-1423 (Pubitemid 32640597)
36. Du X, She E, Gelbart T, Truksa J, Lee P, Xia Y (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science 320:1088-1092 (Pubitemid 351929552)
37. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT (2007) High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13:1096-1101 (Pubitemid 47517510)
38. Ashby DR, Gale DP, Busbridge M et al (2009) Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 95:505-508
39. Ashby DR, Gale DP, Busbridge M et al (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75:976-998
40. Nemeth E, Valore EV, Territo M et al (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101:2461-2463 (Pubitemid 36857598)
41. Ford BA, Eby CS, Scott MG, Coyne DW (2010) Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 78(8):769-773
42. Kobold U, Dülffer T, Dangl M et al (2008) Quantification of hepcidin-25 in human serum by isotope dilution micro-HPLC- tandem mass spectrometry. Clin Chem 54:9
43. Kroot JJC, Kemna EHJM, Bansal SS et al (2009) Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 94(12):1748-1752